th international workshop on hiv and aging · newsletter announcement by virology education, n=5,...

www.virology-education.com

EVALUATION REPORT

NEW YORK, NY, USA • 13 - 14 SEPTEMBER 2018

HIV AND AGING9TH INTERNATIONAL WORKSHOP ON

29th International Workshop on HIV & Aging www.virology-education.com

The 9th edition of the International Workshop on HIV & Aging took place on 13 - 14 September 2018 at The New Yorker Hotel in New York, NY, USA, and was attended by 140 participants from 15 countries.This high profile scientific meeting brought together a variety of cross-disciplinary experts and trainees to in order to present and discuss the latest developments and strategies for the future, in an interactive and science - focused setting. The program featured plenary sessions, round table discussions, oral abstract presentations and poster viewing sessions, providing a unique opportunity to meet colleagues in a scientific focused setting. Special attention was given to the empowerment of early career investigators who received a free registration upon acceptance of their abstract.

Needs assessment

The results of needs assessment show that 98% of the respondents (strongly) agreed there is a need for an educational program on clinical management of aging HIV+ individuals. Effect of inflammation on accelerated aging and geriatric assessment of aging HIV+ individuals were identified as the most urgent educational need/research gaps. On average, 94% of the respondents (strongly) agreed that this year’s program met the needs/gaps identified.

Top 5 most interesting lectures• Atherosclerosis in HIV: insights into biology, detection and

management by Ahmed Tawakol, MD

• Metabolic dysfunction and cognition by Norman Haughey, PhD

• Identifying presymptomatic biomarkers for functional decline in people aging with HIV infection by Monty Montano, PhD

• Considerations for the HIV-positive woman during menopause by Sharon Walmsley, FRCPC, MD, MSc

• HIV and the geriome: linking gut dysbiosis to inflammation by Cara Wilson, MD

Top 5 most relevant lectures• Polypharmacy by Catia Marzolini, PharmD, PhD

• Cognitive aging in the era of effective antiretrovirals by Leah Rubin, PhD, MPH

• Considerations for the HIV-positive woman during menopause by Sharon Walmsley, FRCPC, MD, MSc

• Atherosclerosis in HIV: insights into biology, detection and management by Ahmed Tawakol, MD

• Metabolic dysfunction and cognition by Norman Haughey, PhD

Impact

80% of the respondents reported that 50% or more of the program content was new to them. 93% responded that the lectures given in this conference increased their knowledge on clinical management of aging HIV+ individuals. 80% (strongly) agreed that the program was beneficial for the clinical management of their patients. 82% indicated they intend to incorporate the new information into the care of their patients.

Facts and figures

15 countries

11 invited lectures

EXECUTIVE SUMMARY

140 attendees

41 accepted abstracts

1 roundtable discussion

2 poster sessions

15 abstract-driven presentations

XXXXXXXXXXXXXXXXXXXXXXXXX


TABLE OF CONTENTS

Executive summary 2

Meeting description 4

Committees 5

Meeting demographics 7

Participants’ feedback 11• Invited lectures, abstract presentations 11 • Meeting and learning objectives 15• Intent to change 16• Onsite organization, general conference experience 17• Participants’ remarks 18

Needs assessment 18

Conclusion 19

Acknowledgement 20


The annual international Workshop on HIV & Aging was initiated in 2009 as a unique and much needed platform for international scientific exchange on the increasingly recognized problems of HIV and aging. The 2018-edition gathered a cross-disciplinary team of experts and trainees involved in HIV and aging research, in order to present and discuss the latest developments and strategies for the future, in an interactive and science - focused setting.

Meeting objectivesThis meeting aims to:• Facilitate an unbiased and scientific knowledge exchange regarding

HIV and aging, and encouraging early career investigators to actively partake in the workshop

• Summarize and promote the current state of the science regarding HIV and aging and its successful translation and dissemination.

• Foster new and lasting cross-disciplinary partnerships and collaborations between researchers in HIV and aging, in order to improve knowledge sharing, with the end goal of improving the health span of individuals aging with HIV.

Learning objectivesAfter participating in this activity, the participants will be able to:• Identify age-related clinical complications found in the aging HIV-

infected patient; • Integrate the latest scientific research into daily clinical care to improve

the quality of life of these patients;• Identify the future challenges faced by this expanding population of

elderly HIV infected patients.

MEETING DESCRIPTION


ORGANIZING COMMITTEE

COMMITTEES

Charles Boucher, MD, PHD

Erasmus Medical Center, Rotterdam,

The Netherlands

Scott Letendre, MD

University of California,

San Diego, CA, USA

Savita Pahwa, MD, PhD

University of Miami School of

Medicine, Miami, FL, USA

Kristine Erlandson, MD

University of Colorado

Denver, CO, USA

Jules Levin, MS

NATAP, New York, NY,

USA

Jonathan Schapiro, MD

Sheba Medical Center,

National Hemophilia Center,

Tel Hashomer, Israel

Julian Falutz, MD

McGill University, Montreal,

Canada

Joseph Margolick, MD, PhD

Johns Hopkins University,

Bloomberg School of Public

Health, Baltimore, MD, USA

Madhav Thambisetty, MD

National Institutes of Health/

National Institute of Aging,

Bethesda, MD, USA

Charles Flexner, MD

Johns Hopkins University School of

Medicine, Baltimore, MD, USA

David Moore, PhD

University of California,

San Diego, CA, USA

Russell P. Tracy, MD, PhD

University of Vermont College of

Medicine, Burlington, VT,

USA


COMMITTEES

Beau Ances, MD - Washington University in St. Louis, USA

Bruce Brew, MD - St. Vincent’s Hospital, Australia

Daniel Duprez, MD - University of Minnesota (Cardiology), USA

Meredith Greene, MD - UCSF, USA

Steven Grinspoon, MD - Massachusetts General Hospital, USA

Giovanni Guaraldi, MD - Policlinico Modena, Italy

Marcia McDonnell Holstad, PhD - Emory University, USA

Amy Justice, MD PhD - Yale School of Public Health, USA

Jordan Lake, MD MSc - UTHealth, USA

Alan Landay, PhD - Developmental Center for AIDS Research, USA

Michael Lederman, MD - Case Western Reserve University, USA

Avindra Nath, MD - NIH, USA

Eugènia Negredo, MD PhD - Universitat Autònoma de Barcelona, Spain

Molly Perkins, PhD - Emory University School of Medicine, USA

Sean Rourke, PhD - University of Toronto, Canada

Victor Valcour, MD - UCSF, USA

Cara Wilson, MD - University of Colorado, USA

Scientific Committee

Industry Liaison Board

Andrew Clark, MD - ViiV Healthcare, United Kingdom

Richard Haubrich, MD - Gilead Sciences, USA

Christian Marsolais, PhD - Theratechnologies, Canada


USA 86

Portugal 19

Canada 9

Denmark 5

Israel 4

UK 4

Australia 2

Kenya 2

Netherlands 2

Spain 2

France 1

Hong Kong 1

Italy 1

Poland 1

Switzerland 1

TOTAL 140

RemarksIn total140 registrants from 15 countries attended the meeting.

GEOGRAPHICAL DISTRIBUTION OF PARTICIPANTS

MEETING DEMOGRAPHICS

PERCENTAGE OF RETURING AND NEW PARTICIPANTS N=101

•

NEW58%RETURNING42%

Number of participants and accepted

abstracts throughout the years

•


Occupation

N=106

Medical doctor (MD)n=41, 38%

Researcher (PhD), n=25, 23%

Student,n=8, 7%Other,

n=8, 7%

Corporate Professional,n=6, 6%

Pharmacist (PharmD),n=6, 6%

Patient Representative, n=5, 5%

Nurse,n=4, 4%

Governmental Official or Representative; 4; 4%

Type of organization

N=105

(University) Hospitaln=38, 35%

University, n=33, 31%

Industry,n=12, 11%

Other,n=11, 10%

Government Agency,n=7, 6%

Research Institute,n=5, 5%

NGO, n=2, 2%

Remarks

PROFESSIONAL BACKGROUND


The population of this meeting remains stable throughout the years. In 2018, we see a slight increase in MDs (from 36% to 28%) and a slight decrease in those who have identified themselves as researchers (from 28% to 23%).

HIV remains the leading primary area of expertise.

Target audience set for this program are: • Clinicians and scientists working on cardiovascular,

renal, endocrine, neurologic, and metabolic complications of HIV

• Infectious Disease specialists (virologists, immunologists, pharmacologists)

• Geriatricians• Epidemiologists• Geneticists• Policy makers• Community advocates

Primary area of expertise

N=105

HIVn=71, 68%

Other, n=17, 16%

Immunology,n=8, 7%

Gerontology,n=8, 8%

Pharmacology,n=1, 1%

•


Prescriber status

N=105

Non Prescribern=63, 60%

Prescriber, n=42, 40%

PROFESSIONAL BACKGROUND


Average number of patients per year

N=63

Nonen=31, 49%

more than 250, n=16, 26%

51-100,n=4, 6%

51-100,n=4, 6%

151-200,n=3, 5%

1-50,n=3, 5%

101-150, n=2, 3%



COMMUNICATIONWhat is your main motivation to attend?

N=106

Content of the scientific programn=45, 44%

Meeting objectives, n=14, 13%

Opportunity to meet with my colleagues,n=12, 12%

Faculty/ Speakers of the scientific program,n=12, 12%

Experience from previous meeting,n=11, 11%

Free registration as a Young Investigator/a grantee,n=7, 7%

Meeting location, n=1, 1%

How did you become aware of this meeting?

N=106

Referred by colleague / Word of mouthn=32, 31%

Other, n=31, 30%

Invitation from one of the faculty member,n=19, 18%Announcement

through my society/organization,n=11, 11%

Newsletter announcement by Virology Education,n=5, 5%

Invitation from industry,n=3, 3%

Flyer at another Virology Education meeting, n=2, 2%

N=56 Yes No

Did you receive any conference related newsletters 68% 32%

N=53 Too frequent Sufficient Not enough

Frequency of electronic announcements (VE newsletters) 2% 85% 13%

N=48 Yes No

Did the newsletters encourage you to register for this meeting? 67% 33%

What information is lacking in our communication (newsletters/website)?

• Good enough

• Where the next meeting will be, other similar meetings

• Excellent

• Maybe good to promote awareness--topline topics in preliminary egenda/alerts.

• Just registered


Thursday, September 13

Session 1: The geriatric assessment and interventions - 1 N=71

Comprehensive geriatric assessment

Alison Moore, MD, MPH, FACP, AGSF, University of California San Diego, CA, USA

(Strongly) Agree

Neutral (Strongly) Disagree

N/A

Excellent /good Average Fair / Poor

Topic is interesting 94% 6% 0% 0

Content is relevant to my work 81% 18% 1% 0

Speaker performance 91% 9% 0% 0

Cognitive aging in the era of effective antiretrovirals

Leah Rubin, PhD, MPH, Johns Hopkins University, Baltimore, MD, USA

(Strongly) Agree


N/A





Mood disorders and risk of non-communicable disease multi-morbidity among aging adults living with HIV

Jessica Castilho, #1

(Strongly) Agree


N/A



Aging with HIV: I’m fine, thanks for asking.

Nancy Mayo, #2

(Strongly) Agree


N/A



INVITED LECTURES, DEBATES & ABSTRACTS

PARTICIPANTS’ FEEDBACK

Attendees were asked to evaluate each presentation. The Organizing Secretariat distributed 150 feedback forms in both days. An average number of 65 feedback forms were collected each day. An average of 100 participants attended the meeting each day, making the response rate 65%.

•

NUMBER OF PARTICIPANTS PER SESSION

Thursday, September 13th Participants Friday, September 14th

Session 1 117 Session 5 106






Session 2: The geriatric assessment and interventions - 2 N=68

Translating exercise interventions into the community with adults aging with HIVKelly O’Brien, PhD, PT, University of Toronto, Canada

(Strongly) Agree


N/A





Polypharmacy

Catia Marzolini, PharmD, PhD, University Hospital Basel, Switzerland

(Strongly) Agree


N/A





Exercise-induced inflammatory changes among older adults with and without HIV

Melissa Wilson, #3

(Strongly) Agree


N/A



The impact of number of medications on falls in aging persons living with HIV

Leanne Thai, #4

(Strongly) Agree


N/A



Session 3: Mitochondrial medicine N=63

Mitochondrial dysfunction in aging

Brendan Payne, PhD Newcastle University, United Kingdom

(Strongly) Agree


N/A





Atherosclerosis in HIV: insights into biology, detection and management

Ahmed Tawakol, MD Massachusetts General Hospital, Boston, MA, USA

(Strongly) Agree


N/A





Muscle mitochondrial function and contemporary anti-retroviral therapy

Matthew Hunt #5

(Strongly) Agree


N/A



Metabolic syndrome is associated with neurocognitive deficits in persons living with HIV

Jessica Montoya, #6

(Strongly) Agree


N/A





Session 4: Mitochondrial medicine N=58

Immunity and aging: impact of HIV infection

Savita Pahwa, MD, University of Miami, FL, USA

(Strongly) Agree


N/A





Hepatic steatosis is common in both younger and older adults living with HIV and associated with divergent immuno-metabolic profiles

Jordan Lake #7

(Strongly) Agree


N/A



Memory loss: T cell subsets associated with mortality in HIV+ and HIV- veterans

Wyatt McDonnell, #8

(Strongly) Agree


N/A



Friday, September 14

Session 5: Metabolic dysfunction and cognition N=58

Metabolic dysfunction and cognition

Norman Haughey, PhD Johns Hopkins University, Baltimore, MD, USA

(Strongly) Agree


N/A





Effects of Comorbidity Burden and Age on Brain Integrity in HIV

Rowan Saloner, #9

(Strongly) Agree


N/A



Persistent pro-Inflammatory HIV-mediated glycomic alterations associate with neurological impairment during suppressive therapy.

Mohammed Abdel Mohsen, #10

(Strongly) Agree


N/A



The relationship between synaptodendritic neuropathology and HIV-associated neurocognitive disorders is moderated by age

Erin Sundermann, #11

(Strongly) Agree


N/A





Associations of loneliness with cognitive function and quality of life (QoL) among older adults living with HIV

Marianne Harris, #12

(Strongly) Agree


N/A



The relationship between amnestic mild cognitive impairment and biomarkers of inflammation among adults living with HIV

Laura Campbell. #13

(Strongly) Agree


N/A



Session 6: Frailty and sarcopenia N=55

Identifying presymptomatic biomarkers for functional decline in people aging with HIV infection

Monty Montano, PhD

Harvard University, Boston, MA, USA

(Strongly) Agree


N/A





HIV and the geriome: linking gut dysbiosis to inflammation

Cara Wilson, MD

University of Colorado, Denver, CO, USA

(Strongly) Agree


N/A





Frailty phenotype: a clinical marker of age acceleration in the older HIV-infected population

Maria Matilde Sanchez - Conde #14

(Strongly) Agree


N/A



Correlation between HIV-Index (HIVI), Protective Index (PI) and frailty in an HIV ageing population.

Giovanni Guaraldi, #15

(Strongly) Agree


N/A



Session 7: Menopause in HIV+ women N=50

Considerations for the HIV-positive woman during menopause

Sharon Walmsley, FRCPC, MD, MSc

University Health Network, Toronto, Canada

(Strongly) Agree


N/A







Frailty predicts fractures among HIV-infected and uninfected women: results from the Women’s Interagency HIV Study

Anjali Sharma #14

(Strongly) Agree


N/A



Correlation between HIV-Index (HIVI), Protective Index (PI) and frailty in an HIV ageing population.

Giovanni Guaraldi, #15

(Strongly) Agree


N/A



Session 8: Roundtable discussion N=26

Roundtable discussion: policy makers perspective, patient perspective

(Strongly) Agree


N/A



N=49 0% 25% 50% 75% 100%

What percentage of the content was new for you? 6% 14% 41% 39% 0%

MEETING OBJECTIVESN=57 (Strongly )

AgreeNeutral (Strongly )

DisagreeN/A

To facilitate an unbiased and scientific knowledge exchange regarding HIV and aging, and encouraging early career investigators to actively partake in

the workshop95% 5% 0% 1

To summarize and promote the current state of the science regarding HIV and aging and its successful translation and dissemination.

93% 5% 2% 0

Foster new and lasting cross-disciplinary partnerships and collaborations between researchers in HIV and aging, in order to improve knowledge

sharing, with the end goal of improving the health span of individuals aging with HIV.

89% 9% 2% 0

LEARNING OJBECTIVESN=56 (Strongly)

AgreeNeutral (Strongly )

DisagreeN/A

Identify age-related clinical complications found in aging HIV-infected adults. 96% 4% 0% 0

Integrate the latest scientific research into clinical care to improve the quality of life of patients.

87% 11% 2% 2

Identify the future challenges faced by the expanding population of elderly HIV-infected patients.

93% 5% 2% 0



INTENT TO CHANGEN=45 (Strongly)

AgreeNeutral (Strongly)

DisagreeN/A

The lectures given in this conference have increased my knowledge on aging-related issues in HIV+ individuals 93% 7% 0% 0

This program is beneficial for the clinical management of my patients 80% 15% 5% 15I intend to incorporate the new information into the care of my patients 82% 10% 8% 16

I have utilized this information in treatment strategies for my patients prior to this meeting 70% 24% 5% 17

Implementation of the gained knowledge:Yes No N/A

I will be able to implement the knowledge gained without any problems. 68% 32% 0

The following factors may prevent me from the implementations(multiple answers were possible):

The medications/procedures discussed may not be available for my patients. 6%

My current office and practice systems may not accommodate the changes. 22%

My patient population may not be appropriate for the implementation. 26%

My patients may have trouble complying with these changes/ strategies. 12%

These changes may be too time consuming. 26%

Other reason(s): 8%

• Social worker

• In many cases, the evidence base for interactions is not there yet

• A lot of the content presented is still in experimental phase, with little applicability to the clinical context (in my opinion)

POSTER VIEWINGN=53 (Strongly)


DisagreeN/A

The poster sessions were a valuable element to the program 89% 7% 4% 0The combination of the poster sessions and breaks were well scheduled 92% 6% 2% 0

WORKSHOP DINNERN=24 (Strongly)


DisagreeN/A

The workshop dinner was a valuable element to the meeting 96% 4% 0% 1The workshop dinner was a great opportunity for networking 100% 0% 0% 1



ONSITE ORGANIZATIONN=63 Excellent / good Average Fair / poor N/A

Meeting venue 84% 13% 3% 0Meeting rooms 89% 10% 1% 0

Audiovisuals 89% 6% 5% 0Food & Beverage 92% 6% 2% 0

Onsite logistics 95% 2% 3% 0Service level of Conference Secretariat 97% 2% 1% 0

GENERAL CONFERENCE EXPERIENCEN=45 Excellent / good Average Fair / poor N/A

Overall event experience 90% 6% 4% 0Opportunity of networking 88% 10% 2% 0

(Strongly) Agree Neutral (Strongly)Disagree

N/A

Content was presented clearly 92% 6% 2% 0Content is relevant to my practice 83% 10% 7% 0

N=46 (Strongly) Agree Neutral (Strongly) Disagree

N/A

Content was free from commercial bias (product selling) 98% 2% 0% 0

N=89 Too much Sufficient Not enough N/A

Time allocation for discussion 93% 0% 7% 0

Time allocation per presentation 89% 4% 6% 0

N=49 0% 25% 50% 75% 100% N/A

What percentage of the content was new for you? 6% 14% 41% 39% 0% 11

NEEDS ASSESSMENT

Asia Paciific AIDS & Co-infections Conference 2018

18www.virology-education.com

A needs assessment was conducted during the meeting. Results are presented below.

N=67 (Strongly) Agree


N/A

There is a need for a program on clinical management of elderly HIV-infected individuals 98% 2% 0% 2

There is a need for an educational program for jnior HCPs to educate them on the impact of HIV infection on accelerated aging 94% 6% 0% 2

Has this year’s program addressed this gap?

Primary educational needs/gaps Yes No N/A

Effect of aging on cognitive functions (+/- HIV) 17% 94% 4% 2%

Effect of aging on metabolic dysfunction (+/- HIV) 14% 97% 0% 3%

Effect of inflammation on accelerated aging 22% 94% 2% 4%

Effect of exercise on (accelerated) aging 13% 94% 2% 4%

Geriatric assessment in HIV-infected patients 21% 94% 4% 2%

Influence of HIV infection on Frailty/Sarcopenia parameters 13% 92% 3% 5%

Suggestions

• Implementation science - workshop. Translating bench to clinic.

• Please include an aging woman on next panel.

• Address sexuality and aging

• Feedback from community reps: virtually nothing to organize persons living with HIV who are longterm survivors.. No info presented on seniors with HIV and sexuality. Medicinal marijuana is becoming the standard of care for persons with chronic diseases and HIV across the US and Canada The horse is already “out of the barn”. We need to stop stigma on medical marijuana being used to manage pain and nausea, insomnia, etc.

67 responses out of 150 questionnaires distributed.

Remarks

98% agreed that is a need for a program on clinical management of elderly

HIV-infected individuals

95% reported that this year’s program met the gaps identified.


The Organizing Secretariat is pleased with the evaluation results of the 9th International Workshop on HIV & Aging. Most

of the participants were impressed by the quality of the scientific content and the time allocation for the discussions. The

majority also reported that they were satisfied with the overall meeting logistical arrangements and agreed it was a well-

organized event. Both the evaluation results and the participants’ feedback proved the success and the importance of this

conference.

The Organizing Secretariat will invite the Organizing Committee to further discuss the preparation and the development of

the scientific program for the 10th edition of the International Workshop on HIV & Aging, preliminarily scheduled to take

place in October 2019 in New York, NY, USA.

CONCLUSION


PLATINUM LEVEL

GOLD LEVEL

CORPORATE SUPPORT

ACKNOWLEDGEMENTS

THE MEETING IS ENDORSED BY

SUPPORTER CONTRIBUTOR

www.virology-education.com

th international workshop on hiv and aging · newsletter announcement by virology education, n=5,...

Documents